Forus
Every round on record, with the sources behind each and the investors on them.
LATEST ROUND
Series C
$150M · 2026-09-08
TOTAL RAISED · USD
$150M
across 1 round
INVESTORS
9
1 lead
SOURCES
6
from 6 publishers
Every round on record, with the sources behind each and the investors on them.
| Round | Amount | Announced | Lead | Verified | Status | Sources |
|---|---|---|---|---|---|---|
| Series C series C | $150M | 2026-09-08 | Bain Capital | 6 | [ PUBLISHED ] | 6 |
[ VERIFIED ]1.00 read against its primary page [ BUILT WITH ]·[ SEARCH ]found by corroboration·[ SCRAPE ]6 pages read: medcitynews.com, qz.com, bloomberg.com | ||||||
Forus builds an AI-powered network for doctors, pharmacies, payers, biopharma companies and patients that automates the administrative path from prescription to medication access.
| Round | Amount | Announced | Lead |
|---|---|---|---|
| Seed | n/a | 2023 | Pear VC |
| Series A | $30 million | 2024 | not stated |
| Series B | $123M | 2026-05-12 | Accel |
Forus targets a major bottleneck in healthcare: the forms, insurance authorizations, appeals, affordability work and pharmacy routing that can leave more than a third of patients prescribed high-cost or complex medicines without a first dose and can delay treatment for weeks or months. Its funding is a bet that an AI agent assigned to every prescription can scale a national network—already used by thousands of practices, covering all 50 states and 85% of U.S. residential ZIP codes—while its resulting access data helps biopharma companies bring therapies to patients more effectively.
Via Alexandria from FullEnrich: headcount, type, industry
Bain Capital
Accel
BoxGroup
Pear VC
Redpoint
Thrive Capital
Vast Ventures